Investigation Launched into Myriad Genetics: Impact of UnitedHealth Coverage Changes

Investigation of Myriad Genetics, Inc.

Overview

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Myriad Genetics, Inc. (NASDAQ: MYGN). Those who purchased Myriad securities can find more information and assist in this investigation at bgandg.com/MYGN.

Details of Investigation

On October 31, 2024, UnitedHealth Group announced it would stop covering GeneSight, a Myriad genetic test that determines suitable mental health medications. This change will take effect on January 1, 2025. UnitedHealth’s documentation stated that behavioral health tests like GeneSight are “unproven” and “not medically necessary.” Following this news, Myriad’s stock price dropped significantly on November 1, 2024.

Next Steps for Investors

Investors with information related to this situation or who purchased Myriad securities are encouraged to visit bgandg.com/MYGN to assist the investigation. They can also reach out to Peretz Bronstein or Nathan Miller at 332-239-2660.

No Cost for Assistance

The firm operates on a contingency fee basis, meaning they will only collect fees if the court awards compensation for the investors.

Why Choose Bronstein, Gewirtz & Grossman?

The firm is known for representing investors in securities fraud cases. They have recovered hundreds of millions of dollars for clients across the country.

Contact Information

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

Source

Bronstein, Gewirtz & Grossman, LLC